VIP and COVID-19: There are ongoing trials to explore the role of specific therapies for PH, such as ambrisentan, sildenafil, iloprost, iNO, recombinant ACE2, vasoactive intestinal peptide (VIP) analog, and tocilizumab in COVID-19 [27].